Press release
Major Growth Driver Identified in 2025 Colorectal Cancer Drugs Market: Rising Demand For Personalized Medicines Drives Growth In Colorectal Cancer Drugs Market
Colorectal Cancer Drugs Market
What Is the Expected CAGR for the Colorectal Cancer Drugs Market Through 2025?
The market size of drugs for colorectal cancer has noticeably expanded over the past few years. The market is expected to augment from $20.71 billion in 2024 to $21.98 billion in 2025, displaying a compound annual growth rate (CAGR) of 6.2%. The historical period growth is due to the adoption of multimodal strategies, the invention of chemotherapy, advancements in surgical method, the arrival of targeted treatments, clinical tests, and research.
What's the Projected Size of the Global Colorectal Cancer Drugs Market by 2029?
In the coming years, the market size for drugs targeting colorectal cancer is predicted to witness a significant surge. The market is set to expand to a hefty $27.53 billion by 2029, growing at a compound annual growth rate (CAGR) of 5.8%. Factors contributing to this prospective growth include a rise in personalised treatment, the implementation of patient-centric care models, expanded targeted therapies, the adoption of combination therapies and regulatory acceleration. Noteworthy trends impacting this market during the forecast period comprise advancements in immunotherapy, the evolution of precision medicine, the adoption of combination therapies, breakthroughs in biomarker research and usage, and the novelty in clinical trials.
View the full report here:
https://www.thebusinessresearchcompany.com/report/colorectal-cancer-drugs-global-market-report
Top Growth Drivers in the Colorectal Cancer Drugs Industry: What's Accelerating the Market?
The heightened requirement for individualized medications is set to bolster the expansion of the colorectal cancer drugs market in the future. Personalized medicine, or precision medicine, refers to a medical treatment and healthcare approach that factors in unique variations in a patient's genes, environment, and lifestyle. This personalized approach to CRC treatment is revolutionizing care delivery, leading to more personalized and effective patient care. It is expected to persistently fuel the growth of the CRC drugs market as drug development and research increasingly focus on specific genetic and molecular profiles. For example, as reported by the US-based non-profit organization, the Personalized Medicine Coalition, in February 2024, the FDA approved 16 new therapies tailored for patients with rare diseases in 2023. This was a noticeable uptick from only six approvals in 2022. Consequently, the escalating demand for customized medicine serves as a catalyst for the growth of the colorectal cancer drugs market.
Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=2590&type=smp
What Trends Will Shape the Colorectal Cancer Drugs Market Through 2029 and Beyond?
Targeted treatments are already showing progress in improving the life expectancy of patients with metastatic Colorectal cancer, as compared to just chemotherapy. This type of treatment includes hormone therapies, gene expression modulators, apoptosis inducers, angiogenesis inhibitors, immunotherapies, signal transduction inhibitors, and toxin delivery molecules. Due to its focus on cancer cells, causing minimal toxicity to non-target cells, targeted therapy is becoming increasingly significant. Opdivo and Keytruda serve as examples of such targeted treatments.
What Are the Main Segments in the Colorectal Cancer Drugs Market?
The colorectal cancer drugs market covered in this report is segmented -
1) By Type: Vascular Endothelial Growth Factor (VEGF) Inhibitors, Epidermal Growth Factor Receptor (EGFR) Inhibitors, Programmed Cell Death Protein 1 Or PD1 Ligand 1 (PD1 Or PDL1) Inhibitors, BRAF Or MEK Inhibitors, Tyrosine Kinase (TKI) Inhibitors, Immunomodulators
2) By Class: Immunotherapy, Chemotherapy, Other Classes
3) By Distribution Channels: Hospitals Pharmacies, Retail Pharmacies, Other Distribution Channels
Subsegments:
1) By Vascular Endothelial Growth Factor (VEGF) Inhibitors: Bevacizumab, Ramucirumab, Other VEGF Inhibitors
2) By Epidermal Growth Factor Receptor (EGFR) Inhibitors: Cetuximab, Panitumumab, Other EGFR Inhibitors
3) By Programmed Cell Death Protein 1 Or PD1 Ligand 1 (PD1 Or PDL1) Inhibitors: Pembrolizumab, Nivolumab, Other PD1 Or PDL1 Inhibitors
4) By BRAF Or MEK Inhibitors: Vemurafenib, Encorafenib, Trametinib, Other BRAF Or MEK Inhibitors
5) By Tyrosine Kinase (TKI) Inhibitors: Regorafenib, Sorafenib, Other TKI Inhibitors
6) By Immunomodulators: Checkpoint Inhibitors, Other Immunomodulating Agents
Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=2590&type=smp
Which Top Companies are Driving Growth in the Colorectal Cancer Drugs Market?
Major companies operating in the colorectal cancer drugs market include Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca plc, Takeda Pharmaceutical Company Limited, F. Hoffmann-La Roche Ltd., Eli Lilly and Company, Amgen Inc., Astellas Pharma Inc., Servier Laboratories, Eisai Co. Ltd., Sumitomo Dainippon Pharma Co. Ltd., Ipsen SA, Taiho Pharmaceutical Co. Ltd., Kyowa Kirin Co. Ltd., Taiho Oncology Inc., Ono Pharmaceutical Co. Ltd., Daiichi Sankyo Company Limited, Otsuka Pharmaceutical Co. Ltd., Mundipharma International Limited, Teva Pharmaceutical Industries Ltd., Gilead Sciences Inc., Johnson & Johnson Services Inc., Spectrum Pharmaceuticals Inc., Exelixis Inc., Seattle Genetics Inc., Incyte Corporation, Clovis Oncology Inc., Karyopharm Therapeutics Inc.
Which Regions Will Dominate the Colorectal Cancer Drugs Market Through 2029?
North America was the largest region in the colorectal cancer drugs market in 2024. The Middle East is expected to be the fastest-growing region in the global colorectal cancer drugs market share during the forecast period. The regions covered in the colorectal cancer drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=2590
This Report Supports:
1. Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2. Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3. Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4. Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.
Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.
Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info
Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Major Growth Driver Identified in 2025 Colorectal Cancer Drugs Market: Rising Demand For Personalized Medicines Drives Growth In Colorectal Cancer Drugs Market here
News-ID: 4109434 • Views: …
More Releases from The Business Research Company
Soaring Demand Set to Propel Full Body Motion Capture Software Market to $60.12 …
Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Full Body Motion Capture Software Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
The market for full body motion capture software has experienced a swift expansion in recent years. It is projected to rise from $28.19 billion in 2024 to $32.73 billion in 2025, with…
Financial Wellness Software Market Expansion Continues, with Forecast Valuation …
Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Financial Wellness Software Market Size Growth Forecast: What to Expect by 2025?
The market size for financial wellness software has seen a swift expansion recently. Projected growth spans from $2.68 billion in 2024 to $2.96 billion in 2025, with a compound annual growth rate (CAGR) of 10.7%. This unprecedented…
Cloud Adoption Fueling Growth Of Ethernet Storage Fabric Market: A Key Catalyst …
Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
How Large Will the Ethernet Storage Fabric Market Size By 2025?
The market size for ethernet storage fabric has seen a swift expansion in the last few years. It is projected to rise from a value of $2.08 billion in 2024 to $2.37 billion in 2025, demonstrating a compound…
End User Experience Monitoring (EUEM) Market Poised to Hit $8.51 Billion by 2029 …
Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Will the End User Experience Monitoring (EUEM) Industry Market Size Be by 2025?
The market size of end user experience monitoring (euem) has seen a significant increase in the past few years. It is projected to rise from $3.46 billion in 2024 to $4.17 billion in 2025, boasting…
More Releases for Inhibitors
Thymidine Phosphorylase Inhibitors Market - Breaking the Cycle: Angiogenesis Inh …
Newark, New Castle, USA: The "Thymidine Phosphorylase Inhibitors Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Thymidine Phosphorylase Inhibitors Market: https://www.growthplusreports.com/report/thymidine-phosphorylase-inhibitors-market/8826
This latest report researches the industry structure,…
CGRP Inhibitors Market - Break Free from Migraine: CGRP Inhibitors Redefining Re …
Newark, New Castle, USA - The latest report from Growth Plus Reports analyzes the production, potential applications, demand, major manufacturers, and SWOT analysis of the global CGRP Inhibitors Market.
CGRP Inhibitors Market: https://www.growthplusreports.com/report/cgrp-inhibitors-market/9155
The CGRP Inhibitors Market Report assists in determining the optimum distribution methods for certain products as well as possible markets for future product launches. The report also analyses the purchase and supply trends that influence the market's production strategy.…
Immune Checkpoint Inhibitors Market: Current Evidence And Future Perspectives Of …
Stratagem Market Insights delivers key insights for the Immune Checkpoint Inhibitors market in its published report, which include global industry analysis, Size, Growth, Opportunities, Emerging Trends, Challenges, and Geographic Regions over the forecast period (2021-2028). In terms of revenue, the global Immune Checkpoint Inhibitors market is projected to grow at a CAGR of XX% during the forecast period, owing to several factors about which SMI offers detailed insights and forecasts…
Crude Oil Flow Improvers Market by Type (Paraffin Inhibitors, Asphaltene Inhibit …
Global Crude Oil Flow Improvers Market was valued at $1,282 million in 2016, and is anticipated to reach $1,920 million, growing at a CAGR of 5.7% from 2017 to 2023. Crude oil is one of the most actively traded commodities with a stable growth rate globally. It is extracted from remote locations and needs to be transported through pipelines. Transportation of crude oil via pipeline is relatively difficult, owing to…
Immune Check Point Inhibitors Market Immune Check Point Inhibitors Clinical Pipe …
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990
Report Table of Contents
Immune Checkpoint Inhibitors- Introduction to Next Generation Cancer Immunotherapy
1.1 Overview
1.2 History- From Tragedy to Breakthrough
Major Immune Checkpoints Proteins
2.1 Role of Cytotoxic T lymphocyte Antigen-4 (CTLA-4) in Cancer Development
2.2 Role of Programed Cell Death Protein 1 (PD1) in Cancer Development
Mechanism of Action of Immune Checkpoint Inhibitors
3.1 Cytotoxic T lymphocyte Antigen-4…
Global Immune Check Point Inhibitors Market & Immune Check Point Inhibitors Clin …
Immunotherapy represents a paradigm shift in oncology therapy along the multiple fronts. Although, targeted therapy upgrades the underlying signaling defect which results in oncogenesis within the tumor. The immune checkpoint blockade is fundamentally a therapy which directed at the patient's native immune system to tilt the immune homeostasis away from self-tolerance towards cytotoxicity, with the goal of inducing antitumor immunity.
The immune checkpoint inhibitors such as ipilimumab, nivolumab and pembrolizumab…
